Magnolia Foundation

Magnolia Neurosciences is a biotechnology company dedicated to developing a new class of neuroprotective medicines to treat neurodegenerative diseases and prevent neuronal cell death. Co-founded by Accelerator Life Science Partners and based on discoveries from The University of Texas MD Anderson Cancer Center, the company focuses on conditions such as chemotherapy-induced peripheral neuropathy (CIPN) and Alzheimer's disease. Their research targets specific pathways that trigger the death of neurons, aiming to preserve cognitive and sensory function in patients. By addressing the underlying mechanisms of nerve damage, Magnolia Neurosciences seeks to provide transformative therapies for patients suffering from both chronic neurodegeneration and acute injury.